報價延遲最少15分鐘:2026/02/28 13:09 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
17.51 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.33/-2.97
|
|
企業價值
1.25B
|
| 資產負債 |
|
每股賬面淨值
4.08
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatologyand rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F. |
